Q2 EPS Forecast for TScan Therapeutics Lowered by Analyst

TScan Therapeutics, Inc. (NASDAQ:TCRX) – HC Wainwright cut their Q2 2025 earnings estimates for shares of TScan Therapeutics in a report released on Thursday, March 6th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.32) per share for the quarter, down from their prior estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.30) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.30) EPS.

Several other equities research analysts have also recently commented on TCRX. Wedbush reaffirmed an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Barclays dropped their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Finally, Needham & Company LLC decreased their price target on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $9.20.

TScan Therapeutics Trading Down 2.2 %

Shares of TCRX opened at $1.82 on Monday. The stock has a market capitalization of $97.14 million, a P/E ratio of -1.72 and a beta of 0.91. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a fifty day simple moving average of $2.36 and a two-hundred day simple moving average of $3.93. TScan Therapeutics has a twelve month low of $1.71 and a twelve month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $1.43 million.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp boosted its holdings in shares of TScan Therapeutics by 3.9% during the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock valued at $494,000 after acquiring an additional 3,733 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of TScan Therapeutics by 31.2% during the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock valued at $62,000 after acquiring an additional 4,852 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of TScan Therapeutics by 5.2% in the fourth quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock worth $404,000 after buying an additional 6,550 shares during the last quarter. Finally, Woodline Partners LP boosted its holdings in shares of TScan Therapeutics by 6.7% in the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock worth $352,000 after buying an additional 7,282 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.